CBS and neoplasm: Accordingly, early trials should prospectively stratify patients by CBS/CSE/3-MST expression (prognostic in ovarian cancer and likely predictive of sulfur-targeted strategies), choose release kinetics (slow vs. rapid) to match the intended mechanism (signaling modulation vs. cytotoxicity), and incorporate orthogonal speciation analytics to verify on-target sulfur exposure in tumor versus stroma.